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Abstract
Background Research on the neurobiological foundations of
memory has shown that multiple neurotransmitters play an
important role in memory processing. To study the interaction
between neurotransmitters such as acetylcholine and seroto-
nin, pharmacological models can be used. In this study, we
tested the effects of the muscarinic M1 antagonist biperiden,
acute tryptophan depletion (ATD), and the interaction be-
tween the two on episodic memory using the verbal learning
task.
Methods The study was conducted according to a double-
blind, placebo-controlled, four-way crossover design.
Seventeen participants received biperiden (2.0 mg), ATD
(SolugelP), a combination of both, or a placebo in
counterbalanced order with a wash out of at least 7 days. A
verbal learning task was performed while recording electroen-
cephalography. The task consisted of an immediate and de-
layed recall as well as a recognition part.
Results Results revealed decreased scores on the delayed re-
call after biperiden and ATD separately but no significant
interaction between the two. However, the event-related po-
tential components P3b, N400, and P600 did show an inter-
action during encoding.
Conclusion These results indicate that both BIP and ATD
impair episodic memory. However, an interaction between
the serotonergic and cholinergic system on memory perfor-
mance is not supported.
Keywords Acute tryptophan depletion . Biperiden . Episodic
memory . ERP . Verbal learning
Introduction
The most common age-related neurodegenerative disorder lead-
ing to dementia is Alzheimer’s disease (AD). One of the major
symptoms of this disease is episodic memory impairment, with
impaired learning and recollection of new events. According to
the cholinergic hypothesis formulated by Bartus et al. (1982),
memory and other cognitive problems arise from degeneration
of the basal forebrain cholinergic neurons. Traditionally, the non-
selective cholinergic antagonist scopolamine has been used as a
pharmacological model to mimic episodic memory impairments
as seen in dementia (Ebert and Kirch 1998).
However, it has been suggested that scopolamine is a non-
selective muscarinic receptor antagonist and has widespread
effects in the brain and the body. Consequently, it can be
anticipated that scopolamine may be associated with non-
specific effects on cognitive performance (Klinkenberg and
Blokland 2010). Therefore, a more selective drug may be
more preferable as a pharmacological model for memory def-
icits. Biperiden (BIP) is a selective muscarinic M1 antagonist
used for the adjunctive treatment of Parkinson disease (i.e.,
Akathisia). CholinergicM1 receptors are located mainly in the
cerebral cortex and hippocampus and to a lesser extent in the
body and may therefore have less peripheral side effects
(Klinkenberg and Blokland 2010). For example, in rats, BIP
impaired short-term memory without impairing motor func-
tion (Ebert and Kirch 1998). In humans, similar results have
been found (Sambeth et al. 2015; Wezenberg et al. 2005).
Although most research has investigated the role of acetyl-
choline in AD, cognitive impairments in ADmay not be limited
to impaired cholinergic functioning. AD is associated with a
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decrease in different neurotransmitters, including serotonin and
noradrenaline (Trillo et al. 2013). Moreover, these neurotrans-
mitters have also been found to play a role in cognitive functions.
For example, the acute lowering of the amino acid tryptophan
(ATD) has been used as a model for low central serotonin func-
tioning (Young et al. 1988). It has been established that ATD
impairs episodic memory functioning in patients as well as in
healthy subjects (Mendelsohn et al. 2009; Sambeth et al. 2007).
Since 5-HT is also reduced in AD brains (Trillo et al. 2013), it
could be assumed that ATD could also be considered as a phar-
macological model to test the effects of novel cognition enhanc-
ing drugs (e.g., van Donkelaar et al. 2008).
It is well known that the cholinergic and serotonergic sys-
tems interact anatomically and neurochemically (Cassel and
Jeltsch 1995; Jeltsch-David et al. 2008; Lehmann et al. 2000;
Richter-Levin and Segal 1993; Steckler and Sahgal 1995).
However, a previous human study showed that administration
of the selective serotonin reuptake inhibitor (SSRI) citalopram
in combination with the muscarinic antagonist BIP did not
confirm this finding, since the BIP-induced impairment was
not reversed after administration of citalopram (Sambeth et al.
2015). This finding does not support an interaction between
acetylcholine and serotonin on memory. On the other hand, it
could be argued that this study was not conclusive since
citalopram alone had no effects on memory and that therefore
no interaction effects could be observed.
The aim of the current study was to further examine the
interaction between acetylcholine and serotonin.We tested the
effects of BIP and ATD alone and in combination on episodic
verbal memory performance. Since BIP and ATD clearly im-
pair episodic memory performance in healthy volunteers, we
hypothesized that the combination of both treatments would
decrease the scores on a verbal learning task more than treat-
ment with either BIP or ATD alone would. Although BIP is a
relatively selective model to induce episodic memory impair-
ments and ATD is a more general model, both models have
shown to be effective deficit models. ATD has shown to pro-
duce selective effects on episodic memory without affecting
attention (Mendelsohn et al. 2009). To our knowledge, ATD is
the only model to lower central 5-HT levels and induce mem-
ory impairments in healthy humans. Although the exact nature
of the effects of ATD on the molecular level may not entirely
be understood (van Donkelaar et al. 2011), experimental stud-
ies suggest a relation with brain 5-HT (Crockett et al. 2012).
Next to the behavioral tests, electrophysiological measure-
ments were done, because these have shown to be more sen-
sitive to changes than behavior alone (Luck 2005). Of partic-
ular interest were the P3a and P600 components of the event-
related potential (ERP). The P3a has traditionally been linked
to novelty processing, a prerequisite for memory encoding
and a process that is influenced by the cholinergic system
(Rangel-Gomez and Meeter 2016). We expected BIP to im-
pair the P3a component more than ATD. Related to the P600
component, we expected both BIP and ATD to reduce its
amplitude, because this component is related to memory
encoding and retrieval (Jackson and Snyder 2008; Olichney




Healthy volunteers were recruited fromMaastricht University
through poster advertisements. Participants were required to
be aged between 18 and 35 years. We decided on a restricted
age range because EEG and ERPs can change with age and
can be differentially sensitive to cholinergic modulation
(Bennett et al. 2004; Fjell and Walhovd 2004; Pekkonen
et al. 2005). Participants were also required to have a body
mass index of 18.5–30.0. Female subjects were tested in the
follicular phase of the menstrual cycle. They underwent med-
ical screening before testing, consisting of a medical question-
naire and physical examination.
Exclusion criteria were past or current psychiatric, neuro-
logical, cardiac, gastrointestinal, hematological, hepatic, pul-
monary, or renal illness; pregnancy; lactation; and excessive
alcohol consumption (intake of >20 glasses/week). Subjects
using any medication other than oral contraceptives, having a
first-degree relative with a current or past psychiatric disorder,
and presence of other deficits that could be expected to influ-
ence performance were also excluded. Participants were also
excluded when they smoked more than ten cigarettes per day.
On test days, participants were not allowed to smoke.
All subjects gave a signed informed consent before inclu-
sion and were financially rewarded for their participation. The
study was approved by the Medical Ethics Committee of
Maastricht University.
In total, 17 participants of which 10 were female completed
the study (mean age 22.4 years (S.D. = 3.0, range 19–29)).
Four additional participants were recruited but did not com-
plete all test sessions. Three of them discontinued due to the
disliking of the taste of the protein drink and one stopped after
two test days due to nausea. These participants were excluded
from the analyses.
Treatment and study design
The study was a double-blind, placebo controlled, four-way
crossover design. The order of treatmentswas balanced over four
test days and separated by a wash out period of at least 7 days.
BIP (Laboratorio farmaceutico S.I.T., Mede, Italy) is a mus-
carinic M1 antagonist used for the treatment of Parkinson
symptoms. Peak plasma concentrations are reached 1–2 h after
a single dose administration followed by a rapid decline to 12%
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of the peak value 6 h after intake. Common side effects on the
central nervous system are drowsiness, vertigo, headache, and
dizziness. Peripheral side effects consist of blurred vision, dry
mouth, mydriasis, impaired sweating, abdominal discomfort,
and obstipation. In this study, a dose of 2 mg was used, a dose
well within the range of the recommended doses for BIP.
Furthermore, research has found that an oral dose of 2 mg
impaired cognitive performance in healthy adults (McShane
et al. 2006; Sambeth et al. 2015; Wezenberg et al. 2005).
The tryptophan depletion treatment consisted of a protein
drink containing 100 g of gelatin powder without tryptophan
(TRP−); the composition of the mixture was the same as the
one used in previous studies in which cognition impairing
effects were found (e.g., Evers et al. 2005). Previous studies
in man have shown that this treatment consistently leads to a
70–75% decrease in plasma TRP levels (Evers et al. 2005;
Stenbaek et al. 2016). The placebo treatment consisted of an
identical protein drink to which 1.21 g tryptophan is added
(TRP+). The protein drink was prepared by adding 200 ml of
tap water to 100 g of gelatin powder (Solugel P, PB Gelatins,
Belgium). Both drinks had an identical taste.
Procedure
After inclusion in the study, the participants first performed a
training session. During this session, all cognitive tests were
practiced to familiarize the participants with the study proce-
dures and minimize procedural learning effects.
Each test day started with the assessment of the general
status, filling in questionnaires and taking a blood sample.
This was followed by the intake of either the ATD or balanced
drink. Three hours after the intake of the drink, the participants
received the capsule containing either BIP or a placebo. During
the waiting period, participants were placed in a room where
they could study, read, use their laptop, or watch television.
After this, the participants were offered a low-TRP, low-
protein lunch. Four hours after the intake of the drink, the
experiment was started.
Questionnaires
To assess subjective alertness, the Bond and Lader mood scale
was used (Bond and Lader 1974). Adverse effects were
assessed with a self-report questionnaire consisting of 31 pos-
sible complaints to be rated on a 4-point scale. Only dry
mouth, sleepiness, nausea, headache, dizziness, fatigue, and
drowsiness were analyzed.
Verbal learning task
The used test is an adapted version of the Rey auditory verbal
learning test (Lezak 1995), which assesses short- and long-
term memory function for verbal information. The test
consisted of a list of 30 monosyllabic words (18 nouns and
12 adjectives) in English, which were presented on a computer
screen for 1 s. The words were presented three times in the
same sequence, and immediately after presentation, a free re-
call phase followed (immediate recall; sum of words recalled
in three trials). Thirty minutes after the third trial, the partici-
pant was asked to freely recall as many words as possible
(delayed recall). Subsequently, a recognition test was present-
ed, consisting of all former words and 30 new but comparable
words (distracters). The words were shown on a computer
screen for a max of 1500 ms, and participants were asked to
rate whether they were presented in the learning trials by a
Byes/no^ response. A new trial started 3500 ms after presen-
tation of the previous word.
Each session, a different word list was presented to the
participants. The order of the lists was balanced across assess-
ments. Outcomemeasures were the number of words correctly
recalled in the three immediate recall trials and delayed recall
phase. In the recognition test, mean reaction times were mea-
sured in milliseconds as well as the number of correct recog-
nized words.
The main behavioral outcome measures were based on
recall scores. In contrast, the ERP-related measures were
extracted during encoding and recognition. The ERP
components P3a, P3b, N400 and P600 were compared to
examine whether the initial stimulus processing during the
learning trials differs from word to word. Finally, ERPs for
the old and new items during the recognition task were
measured.
EEG acquisition
An EEG cap was used to place a set of 32 EEG electrodes
according to the international 10–20 system (Jasper 1958), but
only the midline electrodes (Fz, FCz, Cz, CPz, Pz) were used
in the statistical analysis. A reference and a ground electrode
were placed at the linked mastoids and at the forehead, respec-
tively. Eye movements were detected by horizontal and verti-
cal electro-oculogram (EOG) recordings. Before electrode at-
tachment, the positions were cleaned with alcohol and slightly
scrubbed with a gel in order to provide good conductance.
Both EEG and EOG were filtered between 0.01 and 100 Hz
and sampled at 1000 Hz.
The EEG data was analyzed using Vision Analyzer 2
(Brain Products, Gilching, Germany) software. Epoch files
were made from 100 ms before stimulus onset until 1000 ms
after onset, using the last 100 ms before stimulus onset as
baseline. High-pass (1 Hz) and low-pass (30 Hz) filters were
applied offline. The segments were checked for EOG activity
(visually and by using the Gratton and Coles method in Vision
Analyzer) and other artifacts and excluded if an artifact oc-
curred during the first 1000 ms after stimulus presentation.
Next, averages were calculated for each stimulus type and
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treatment. The grand average was used to determine the ERP
components. For the VLT, peak detection windows were de-
fined as the most positive or negative value between the fol-
lowing intervals: P3a 210–290 ms, P3b 290–360 ms, N400
340–470 ms, and P600 450–700 ms. For the VRT, the win-
dows were P3a 210–280 ms, P3b 280–350 ms, N400 310–
460 ms, and P600 430–720 ms.
Statistical analysis
In this study, a 2 × 2 × 5 factorial design was used to analyze the
outcome variables using repeated measures multivariate analy-
ses of variance (MANOVA). The two treatment conditions
(ATD: ATD or placebo and BIP: BIP or placebo) and electrode
positions were entered as within-subject factors. Finally, effect
sizes (η2partial) were calculated to determine the magnitude of
the effects (see Table 3). All statistical analyses were done by
using the Statistical Package for the Social Sciences for
Windows (version 24; SPSS Inc., Chicago, IL, USA).
Adverse effects and the Bond and Lader were also analyzed
using ANOVA. For this analysis, differences between effects at
test vs. at baseline were taken into account. Post hoc testing was
performed with a least significant difference (LSD) test.
Results
Questionnaires
B&L alertness: No significant effects of BIP or ATD (F(1,
16) = 1.21, p = .288 and F(1, 16) = 2.755, p = .116, respec-
tively). No interaction between the two treatments was found
(F(1, 16) = .571, p = .461).
As for the adverse effects, participants reported a signifi-
cant increase in drowsiness after biperiden as compared to
placebo (F(1, 16) = 7.314, p = .016, ηp2 = .314). Neither of
the other aspects was affected by any of the treatments, nor
were interactions between biperiden and ATD found (see the
most common adverse effects in Table 1).
Behavioral results of VLT and VRT
Figure 1 as well as Table 2 show the total immediate and the
delayed recall scores during the VLT for all four treatments.
ATD significantly impaired immediate recall (F(1, 16) = 9.04,
p < .009, ηp
2 = 0.361). BIP, however, did not significantly
impair immediate recall (F(1, 16) = 1.98, n.s.). Additionally,
there was no interaction between the two treatments for im-
mediate recall (F(1, 16) = .358, n.s.).
As for the delayed recall, both ATD and BIP significantly
impaired memory performance (F(1, 16) = 13.71, p < .003,
ηp
2 = 0.461 and F(1, 16) = 5.61, p < .032, ηp
2 = 0.259, re-
spectively). Again, no interaction between the two treatments
was found (F(1, 16) = .885, n.s.; see Fig. 1c).
Furthermore, difference scores reveal no differences
between treatment conditions (see Fig. 1d). Paired samples t
test showed that there was no significant difference in the
scores for BIP (M = 3.00, SD = 5.39) and ATD (M = 2.94,
SD = 4.67); t(16) = −0.06, p = 0.957). Furthermore, the diffe-
rence between ATD and COMBI (M = 4.12, SD = 4.18) was
also not significant: t(16) = −0.90, p = 0.384. And, the
difference between BIP and COMBI was not significant:
t(16) = −1.09, p = 0.322.
In the recognition test, participants significantly recognized
more new than old words correctly (F(1, 16) = 5.39, p < .035),
but they responded faster to old than newwords (F(1, 16) = 8.56,
p < .011). Neither of the two treatments affected recognition
performance and reaction time during the delayed recognition
paradigm, nor did the treatments interact (all F values < 2.75),
(see Table 2).
EEG results of VLT
P3a
A main effect of BIP was found for the main analysis (F(1,
16) = 8.29, p < .012), (see Fig. 2 and Table 3). BIP signifi-
cantly increased the P3a amplitude. ATD did not affect the P3a
amplitude (all F values < 0.78).
Table 1 Mean difference scores
as change from baseline (SE) for
the outcome variables of the
questionnaires
Placebo BIP ATD Combination
Bond and Lader alertness −125.41(36.21) −120.82 (35.67) −53(34.39) −107.12 (33.19)
Adverse effects
Headache 0.47 (.21) 0.41 (.17) 0.24 (.20) 0.29 (.14)
Sleepiness 0.53 (0.29) 0.53 (0.21) 0.35 (0.28) 0.41 (0.19)
Dizziness −0.06 (0.06) 0.06 (0.6) −0.06 (0.10) 0.06 (0.10)
Nausea 0.18 (0.13) 0.24 (0.19) 0.0 (0.09) 0.18 (0.18)
Dry mouth −0.12 (0.08) −0.06 (0.16) 0.06 (0.18) −0.06 (0.14)
Fatigue 0.47 (0.21) 0.65 (0.19) 0.24 (0.28) 0.41 (0.17)
Drowsiness 0.77 (0.20) 0.77 (0.22) 0.47 (0.24) 0.59 (0.17)
Negative numbers indicate a decrease and positive numbers indicate an increase in the feeling
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P3a latency was not affected by any of the treatments (all F
values < 2.75).
P3b
A significant interaction between BIP and ATD was found in
the main analysis (F(1, 16) = 5.26, p < .037). This effect was
caused by the fact that ATD treatment reduced P3b amplitude
as compared to the other treatments, indicating that BIP re-
versed this decrement.
None of the other measures related to any of the treatments
in the main analysis for latency were significant (all F
values < 2.50).
N400
A significant interaction between BIP and ATD was found for
the main analysis (F(1, 16) = 9.92, p < .007). The N400
amplitude was more negative after BIP and after ATD treat-
ment than after placebo. Furthermore, placebo and the com-
bined treatment did not differ, indicating that the amplitude
normalized after combined treatment.
P600
An interaction between BIP and ATD was found in the main
analysis (F(1, 16) = 7.67, p < .015). The P600 was reduced
after BIP and after ATD but only to a minor extent after the
combined treatment.
Regarding latency, an interaction between ATD and
electrode was found in the main analysis (F(4, 64) =
3.783, p < .021. Whereas the latencies were similar for
all electrodes after Placebo, ATD reduced the latency at
CPz and Pz.
Regarding latency, no interactions were found in the main
analysis (all F values < 0.93).
Fig. 1 The number of words
recalled during each immediate
recall trial (a); the total number of
words recalled during the three
immediate recall trials (b); the
number of words recalled during
the delayed recall (c); placebo—
condition difference scores for the
delayed recall (d)
Table 2 Mean scores (SE) for the
outcome variables of the verbal
learning task and verbal
recognition task
Placebo BIP ATD Combination
Verbal learning task (VLT)
Total immediate recall 52.35 (3.24) 49.06 (3.53) 46.53 (3.45)* 45.00 (3.23)*
Delayed recall 20.41 (1.43) 17.41 (1.65)* 17.47 (1.58)* 16.29 (1.42)*
Verbal recognition task (VRT)
Number of correctly recognized words 27.24 (0.49) 26.88 (0.75) 27.50 (0.64) 26.74 (0.69)
Mean reaction time for correct responses
to old and new stimuli (in ms)
662 (13) 659 (13) 677 (17) 686 (22)
*p < 0.05 (of note, asterisks are shown for both BIP and combination or ATD and combination because they
together reflect the main effect of the treatment)
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EEG results of VRT
P3a
A main effect of BIP was found for P3a amplitude (F(1,
16) = 12.94, p < .003), (see Fig. 2 and Table 3). P3a amplitude
was increased after BIP as compared to placebo. No other
effects related to any of the treatments were found regarding
either the amplitude or the latency.
P3b
An interaction between BIP and ATDwas found for the latency
of the P3b (F(1, 16) = 7.81, p < .014). P3b latency was reduced
both after ATD and after BIP as compared to placebo but was
not different from placebo after the combined treatment.
An interaction between BIP and electrode was found (F(4,
64) = 7.746, p < .003). This was caused by the fact that the P3b
amplitude for BIP was larger than for placebo at Fz and FCz,
although this difference was not present for Cz, CPz, and Pz.
N400
A malin effect of BIP was found for N400 amplitude (F(1,
16) = 11.10, p < .005). Amplitude after BIP was less negative
than after placebo. The ATD and BIP conditions separately
did not differ from placebo.
BIP also significantly interacted with electrode (F(4,
64) = 6.725, p < .006). BIP was less negative than placebo
at all electrodes, but this effect was most pronounced for the
Fz, FCz, and Cz electrode positions.
With regard to N400 latency, a main effect of BIP was
found (F(1, 16) = 6.32, p < .024). Latency was slightly in-
creased after BIP.
P600
No significant effects related to any of the treatments were
found for the amplitude of the P600 (all F values < 1.39).
Table 3 Mean amplitude in μV
(SE) VLT Placebo BIP ATD Combination BIP ATD Interaction
P3a 4.9 (0.9) 5.7 (0.8) 4.8 (0.9) 5.4 (0.9) F 8.29* 0.78 0.17
ηp
2 0.341 0.046 0.011
P3b 2.8 (0.5) 2.9 (0.5) 1.9 (0.7) 3.1 (0.6) F 3.41 0.66 5.26*
ηp
2 0.176 0.040 0.247
N400 −2.8 (0.5) −3.3 (0.4) −3.9 (0.5) −2.3 (0.5) F 0.37 1.48 9.92*
ηp
2 0.023 0.085 0.383
P600 4.9 (0.5) 4.2 (0.4) 4.1 (0.3) 4.5 (0.4) F 0.57 0.65 7.67*
ηp
2 0.034 0.039 0.324
VRT Placebo BIP ATD Combination BIP ATD Interaction
P3a 3.7 (0.8) 4.7 (0.9) 3.4 (0.8) 5.0 (0.9) F 12.94* 0.00 0.36
ηp
2 0.447 0.00 0.022
P3b 1.7 (0.8) 2.5 (0.6) 2.10 (0.8) 2.8 (0.8) F 3.83 1.92 0.04
ηp
2 0.193 0.107 0.002
N400 −4.4 (0.7) −3.6 (0.6) −4.5 (0.8) −3.4 (0.7) F 7.05* 0.02 0.23
ηp
2 0.306 0.001 0.014
P600 7.7 (0.8) 7.5 (0.8) 8.2 (0.7) 7.5 (0.6) F 1.39 0.44 0.61
ηp
2 0.080 0.027 0.036
For each effect, F values and effect sizes (ηp2 ) are reported
*p < 0.05































Fig. 2 Grand average across participants of the ERPs elicited by the
treatments at the Cz electrode
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Discussion
The aim of this study was to examine the effects of BIP and
ATD on episodic verbal memory and their electrophysiologi-
cal correlates in healthy adults. Additionally, the interaction
between the serotonergic and cholinergic system was exam-
ined by combining both treatments. BIP significantly de-
creased the scores for the delayed recall but not for the imme-
diate recall. ATD resulted in lower scores for the immediate
recall as well as for the delayed recall. However, the combi-
nation of BIP and ATD did not impair the memory perfor-
mance more than for each treatment alone. Thus, no interac-
tions between BIP and ATD were found. Analysis of the EEG
data revealed that BIP increased the amplitude of the P3a
component for both the acquisition phase and the recognition
phase of the verbal learning task.
The current study again confirms that an M1 antagonist is
effective in inducingmemory impairment in a verbal word learn-
ing task.However, in our study, BIP only impaired delayed recall
whereas in two other studies, immediate as well as delayed recall
was impaired (Wezenberg et al. 2005; Sambeth et al. 2015). In
all studies, similar doses and drug-test intervals were used. Of
note, a more detailed analysis revealed that BIP impaired the
performance at the third trial of the immediate recall
(p < 0.05). Thus, there is some support that BIP also impaired
immediate recall, although not as robust as in previous studies.
During the memory encoding phase and the recognition
trials, a significant effect of BIP was found for the amplitude
of the P3a component. The amplitude of this component was
larger after BIP than after the other treatments. As mentioned
previously, this component is involved in novelty processing;
larger amplitudes correspondwith stimuli that are perceived as
more novel (Rangel-Gomez and Meeter 2016). This may re-
late to a poorer immediate recall performance after BIP treat-
ment since the stimuli remain more novel even after three
presentations.
According to the literature, the amplitude of the N400 de-
creases after repeated stimuli, thus indicating that stimuli are
consolidated (Olichney et al. 2011). Surprisingly in this study,
even though the N400 amplitude was as expected increased
during encoding, the amplitude was less negative after BIP
compared to the other treatments during the verbal recognition
task. This suggests that in the BIP condition, words were con-
solidated better compared to the other condition. This is against
our expectations and behavioral findings since we expected
BIP to impair memory-related components. Possibly, the rela-
tively large amplitude of the P3b component may have influ-
enced the N400 amplitude in this condition. However, this
probably does not fully explain the decreased N400 amplitude.
Lastly, we hypothesized that the P600 amplitude would be
decreased after BIP; however, we did not find any effects on
both encoding and recognition. Altogether, EEG data suggest
BIP mostly affects novelty processing, whereas other memory-
related ERP components were not affected by BIP.
It is presumed that ATD impairs cognition by lowering
central serotonin levels (Klaassen et al. 1999; but see van
Donkelaar et al. 2011). According to a review (Mendelsohn
et al. 2009), most studies using acute tryptophan depletion
report impaired delayed recall but not immediate recall.
Also, they concluded that ATD impairs the consolidation
and to a lesser extent encoding of episodic memory. The pres-
ent study corroborates these previous studies and further sup-
ports the notion that ATD has a robust effect on verbal mem-
ory performance. The impairment is consistently found on
delayed recall, whereas the effects on immediate recall seem
to depend on the sex of the subjects (Sambeth et al. 2007),
larger impairments being found in females. In the current
study, 10 of 17 subjects were female, which may explain the
effect on immediate recall in our study.
Even though memory performance on both the immediate
and delayed recall was decreased after ATD, the task-related
ERPs were less affected by ATD. Unlike BIP, ATD did not
affect the P3a component that reflects novelty processing.
This could indicate that ATD and BIP both act on different
processes in the brain. Apparently, ATD has a different effect
on brain processing and 5-HT may not be involved in novelty
processing (Rangel-Gomez and Meeter 2016). On the other
hand, some genetic studies suggest a role of the 5-HT2 recep-
tor (Schott et al. 2011) and the 5-HT transporter (Enge et al.
2011). These mixed findings on the role of 5-HT on novelty
processing is likely to be related to the type of manipulation of
the 5-HT system. The N400 was more negative after ATD as
compared to placebo during the encoding phase. Given that it
should decrease after repeated stimulation (Olichney et al.
2011), the increased N400 indicates that ATD likely impairs
processes related to consolidation.
The objective of the current study was to examine whether
there would be additive effects of BIP and ATD treatments
(i.e., an interaction effect). We expected that the scores for
the verbal learning task would be decreased more as compared
to both the ATD and BIP alone conditions. In contrast to our
hypothesis, the behavioral results did not reveal an additive
effect of the combined ATD BIP treatment. No interaction
effects were found for the behavioral data for the immediate
and delayed recall or the recognition test. The ERP data result-
ed in mixed outcomeswhich are difficult to interpret in relation
to the memory performance. Some interactions between BIP
and ATD were found for the amplitudes of the P3b, N400, and
P600 components on the encoding trials. However, the inter-
pretation of this interaction is not easy since no interaction on
memory performance was found. During the verbal recogni-
tion task, no interactions on amplitude were found at all.
The ATD method is based on the assumption that the de-
pletion of tryptophan, a precursor of 5-HT, leads to decreased
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levels of 5-HT in the brain. Currently, this appears to be the
most relevant model to affect central 5-HT functioning.
However, the notion that ATD influences memory only by
lowered central 5-HT levels was questioned recently (van
Donkelaar et al. 2011). It was suggested that alternative path-
ways may also lead to memory impairments (e.g., LTP/
NMDA related mechanisms). For example, ATD leads to low-
er kynurenic acid levels and has been associated with cogni-
tive performance (Kennedy et al. 2015). However, there is no
clear evidence that the changes in kynurenic acid levels affect
the cholinergic neurotransmission (e.g., Stone and Darlington
2013). On the other hand, it has been claimed that the ob-
served effects after ATD are closely related to 5-HT-related
functions (Crockett et al. 2012). Although the exact nature of
the molecular effects of ATD is not fully understood, the cur-
rent study provides no support for an interaction between ATD
(5-HT or NMDA-related) and BIP (ACh/M1 receptor) on
memory performance. Further studies are needed to further
examine whether this lack of interaction between neurotrans-
mitter systems is related to NMDA or 5-HT.
Related to the discussion above, it should also be noted that
BIP has a selective affinity for the M1 and M4 receptors
(Perez et al. 2006), whereas ATD has a global effect on sero-
tonin and kynurenine (Badawy and Dougherty 2016;
Kennedy et al. 2015). Even though in this study a selective
and a global challenge were combined, both methods are as-
sumed to act on different neurotransmitter systems in the
brain. Since both treatments impair memory performance,
we expected a stronger impairment after a combined treat-
ment. However, the present study did not find support for an
additive interaction effect. On the other hand, this does not
exclude that both systems could interact, as was shown with
the EEG-related measures. Further studies could explore the
interaction between acetylcholine and more specific seroto-
nergic drugs (e.g., Wingen et al. 2007).
The lack of relation between EEGmeasures and behavioral
measures could be explained by at least two factors. First, the
ERPs were recorded during the encoding phase and the rec-
ognition phase, whereas the effects on memory performance
were observed during the immediate and delayed recall test.
Since these are independent processes of memory, the ERPs
may not directly relate to the recall scores. Secondly, the ef-
fects of ATD and BIP could be related to processing in brain
areas that were not detected by the scalp electrodes. For ex-
ample, it has been found that the hippocampus is important for
word learning (Shtyrov 2012).
The results for the treatment effects on the ERP compo-
nents are more ambiguous compared to the behavioral data.
Most effects were found related to the amplitude of the P3a
component, implicating that novelty detection was affected.
Related to BIP treatment, this indicates impaired encoding.
Likewise, the P3a amplitude was increased for the recognition
trials in the presence of BIP, indicating that impaired encoding
is a longer lasting process that can last up until the delayed
recall. The N400 was impaired after ATD, indicating that this
manipulation rather leads to impaired consolidation.
Significant interactions were found for the amplitude of the
P3b, N400, and P600 during encoding. Altogether, we can
conclude that the presence of BIP and ATD alone did impair
episodic memory. However, against our expectations, an in-
teraction between BIP and ATD was not found.
In conclusion, this study does not support the notion that
the serotonergic and cholinergic systems interact in processes
related to learning andmemory on the behavioral level. On the
electrophysiological level, there are indications that a possible
interaction exists. Further research is needed to scrutinize the
exact nature of the interaction between the cholinergic and
serotonergic systems in relation to memory functions.
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